Project: A novel therapeutic antibody and companion diagnostic for non-ischaemic cardiac remodelling

NOVA-CARE aims to establish preclinical efficacy in mouse and porcine disease models for a novel therapeutic monoclonal antibody (mAb) to prevent non-ischaemic heart failure (NI-HF) by targeting EDA-fibronectin (EDA). This protein is upregulated during adverse cardiac remodelling, which leads to heart failure (HF). In addition, a companion diagnostic will be developed using biomarkers linked to EDA expression, to identify patients at risk for developing NI-HF, and to optimize mAb treatment.

Acronym	NOVA-CARE (Reference Number: 10421)
Duration	01/10/2016 - 01/10/2019
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 5

Project partner

Number	Name	Role	Country
24011	EnCare Biotech B.V.	Coordinator	Netherlands
24012	University Medical Center Utrecht	Partner	Netherlands
24013	Firalis SAS	Partner	France
24014	Fusion Antibodies	Partner	United Kingdom